Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2165/00003088-200038010-00001PMID 10668856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion

  2004cited by this paper
• Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin

  2004cited by this paper
• Intracellular glutathione and cytotoxicity of platinum complexes

  2004cited by this paper
• Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits

  2004cited by this paper
• Phase I study of oxaliplatin in patients with advanced cancer

  2004cited by this paper
• Therapeutic implications of circadian rhythms in cancer patients.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

  2000cited by this paper
• Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats

  1999cited by this paper
• Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.

  1999cited by this paper
• High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.

  1999cited by this paper
• Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

  1999cited by this paper
• Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

  1999cited by this paper
• Biotransformations of oxaliplatin in rat blood in vitro

  1999cited by this paper
• Oxaliplatin pharmacokinetics during a four-hour infusion.

  1999cited by this paper
• A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

  1999cited by this paper
• Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model

  1999cited by this paper
• Activity of oxaliplatin against human tumor colony-forming units.

  1998cited by this paper
• Pharmacokinetics and safety profile of oxaliplatin.

  1998cited by this paper
• Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

  1998cited by this paper
• Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice

  1998cited by this paper
• Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters

  1998cited by this paper
• Chronopharmacokinetics

  1998cited by this paper
• [Phase I clinical study of oxaliplatin].

  1998cited by this paper
• Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

  1998cited by this paper
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

  1998cited by this paper
• Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.

  1998cited by this paper
• Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

  1997cited by this paper
• Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.

  1997cited by this paper
• Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.

  1997cited by this paper
• Circadian‐system alterations during cancer processes: A review

  1997cited by this paper
• Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

  1997cited by this paper
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

  1997cited by this paper
• Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice.

  1997cited by this paper
• Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.

  1996cited by this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

  1996cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper
• Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

  1996cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.

  1994cited by this paper
• Spontaneous or imposed circadian changes in plasma concentrations of 5‐fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer

  1994cited by this paper
• Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.

  1994cited by this paper
• Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

  1994cited by this paper
• Dose‐dependent pharmacokinetics: Experimental observations and theoretical considerations

  1994cited by this paper
• Comparative pharmacokinetics of oxaliplatin (L‐OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time

  1994cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994cited by this paper
• Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

  1993cited by this paper
• Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian‐carcinoma cell lines

  1993cited by this paper
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma.

  1992cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Chronobiology of Circulating Blood Cells and Platelets

  1992cited by this paper
• A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

  1992cited by this paper
• Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes.

  1992cited by this paper
• Clinical pharmacokinetics of carboplatin.

  1991cited by this paper
• Clinical Pharmacokinetics of Carboplatin

  1991cited by this paper
• Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity.

  1991cited by this paper
• Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity

  1991cited by this paper
• Circadian changes in estimated hepatic blood flow in healthy subjects.

  1991cited by this paper
• Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.

  1990cited by this paper
• Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.

  1990cited by this paper
• Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.

  1990cited by this paper
• Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

  1990cited by this paper
• Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry

  1990cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.

  1989cited by this paper
• Physiopathological alterations of alpha 1 acid glycoprotein temporal variations: implications for chronopharmacology.

  1989cited by this paper
• Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients.

  1988cited by this paper
• Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

  1988cited by this paper
• Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.

  1988cited by this paper
• Pharmacokinetics of carboplatin after i.v. administration.

  1987cited by this paper
• Circadian rhythm in the membrane of circulating human blood cells: microviscosity and number of benzodiazepine binding sites. A search for regulation by plasma ions, nucleosides, proteins or hormones.

  1987cited by this paper
• Differences between young and elderly subjects in seasonal and circadian variations of total plasma proteins and blood volume as reflected by hemoglobin, hematocrit, and erythrocyte counts.

  1986cited by this paper
• Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

  1986cited by this paper
• Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin

  1986cited by this paper
• Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II).

  1985cited by this paper
• Kinetics of the reaction of cis-platinum compounds with DNA in vitro.

  1985cited by this paper
• Antitumor activity of l-OHP in mice.

  1985cited by this paper
• Circadian timing of cancer chemotherapy.

  1985cited by this paper
• Time dependency in plasmatic protein binding of cisplatin.

  1985cited by this paper
• Drugs five years later. Cisplatin.

  1984cited by this paper
• Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

  1984cited by this paper
• High-dose cisplatin in hypertonic saline.

  1984cited by this paper
• Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats.

  1982cited by this paper
• Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.

  1982cited by this paper
• Circadian time dependence of cisplatin urinary kinetics

  1982cited by this paper
• Clinical kinetics of intact cisplatin and some related species

  1981cited by this paper
• Clinical kinetics on intact cisplatin and some related species.

  1981cited by this paper
• 1,2-Diaminocyclohexane platinum derivatives of potential clinical value.

  1980cited by this paper
• Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers.

  1980cited by this paper
• Anti-tumour platinum complexes : relationships between chemical properties and activity

  1978cited by this paper
• Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form.

  1978cited by this paper
• Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

  1977cited by this paper
• Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes.

  1976cited by this paper
• Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode

  1965cited by this paper

• When adipose meets inflammation: a novel adiposity–inflammation signature predicts prognosis and chemotherapy benefit in locally advanced gastric cancer

  2026influential citation
• Artificial intelligence generated 3D body composition predicts dose modifications in patients undergoing neoadjuvant chemotherapy for rectal cancer

  2025cites this paper
• A case report of insulin autoimmune syndrome induced by drugs for colorectal cancer

  2025cites this paper
• Advancing clinical outcome predictions via incorporating pharmacokinetic simulations into in vitro testing - a colorectal cancer example

  2025cites this paper
• Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models.

  2025cites this paper
• Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state

  2025cites this paper
• Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models

  2025cites this paper
• Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer.

  2024cites this paper
• Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Quercetin-Induced Glutathione Depletion Sensitizes Colorectal Cancer Cells to Oxaliplatin

  2023cites this paper
• Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal Cancer.

  2023cites this paper
• Recovery of dialysis-dependent acute kidney injury after cessation of oxaliplatin

  2023cites this paper
• Treatment of Liver Metastases With Focused Ultrasound and Microbubbles in Patients With Colorectal Cancer Receiving Chemotherapy.

  2023cites this paper
• Chronotherapy in Glioblastoma: State of the art and future perspectives

  2023cites this paper
• Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

  2023cites this paper
• Ultrasound and Microbubbles Increase the Uptake of Platinum in Murine Orthotopic Pancreatic Tumors.

  2023cites this paper
• Reactions of cisplatin and oxaliplatin with penicillin G: implications for drug inactivation and biological activity

  2022cites this paper
• The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer.

  2022cites this paper
• Introduction of Fluorine into Antitumor-Active Dinuclear Platinum(II) Complexes Leads to Modulation of In Vivo Antitumor Activity in Mice.

  2022cites this paper
• Comparative Analysis of Clinical Trials, Therapeutic Uses, Pharmacokinetics, and Adverse Effects of Approved Platinum-Based Drugs

  2022cites this paper
• Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

  2022cites this paper
• Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin.

  2022cites this paper
• Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin

  2022cites this paper
• Blockade LAT1 Mediates Methionine Metabolism to Overcome Oxaliplatin Resistance under Hypoxia in Renal Cell Carcinoma

  2022cites this paper
• Sex and Circadian Timing Modulate Oxaliplatin Hematological and Hematopoietic Toxicities

  2022cites this paper
• Tuning the anticancer properties of Pt(ii) complexes via structurally flexible N-(2-picolyl)salicylimine ligands

  2022cites this paper
• Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes

  2021cites this paper
• Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy

  2021cites this paper
• Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

  2021cites this paper
• Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy

  2021cites this paper
• Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect

  2021cites this paper
• Population Pharmacokinetic Model-Based Evaluation of Intact Oxaliplatin in Rats with Acute Kidney Injury

  2021cites this paper
• Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS

  2021cites this paper
• Macrolipasemia secondary to colon cancer chemotherapy: a case report

  2021cites this paper
• Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial

  2021cites this paper
• Determining Chemotherapy Agents in Saliva through Spectrometry and Chromatography Methods Correlated with Periodontal Status in Oncology Patients

  2021cites this paper
• Demonstration of treatment planning software for hyperthermic intraperitoneal chemotherapy in a rat model

  2021cites this paper
• Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives

  2021cites this paper
• In-vitro evaluation of dendrimeric formulation of oxaliplatin

  2021cites this paper
• Interstrand Crosslink Repair: New Horizons of DNA Damage Repair

  2021cites this paper
• Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin

  2020cites this paper
• Cisplatin's dual-effect on the circadian clock triggers proliferation and apoptosis

  2020cites this paper
• Effect of renal function on neutrophil decreases following eribulin administration

  2020cites this paper
• Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

  2020cites this paper
• Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O^O ligands

  2020cites this paper
• Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

  2020cites this paper
• A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion.

  2020cites this paper
• Conventional chemotherapy

  2020cites this paper
• In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model

  2020cites this paper
• FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study

  2020cites this paper
• Exploring the DNA Binding Mechanisms of Platinum-Based Chemotherapeutic Agents: State of Art and Perspectives of the Candidates

  2020cites this paper
• Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy

  2020cites this paper
• Synthesis and redetermination of the crystal structure of salicylaldehyde N(4)-morpholinothiosemicarbazone

  2019cites this paper
• Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art

  2019cites this paper
• L‐Carnosine protects against Oxaliplatin‐induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf‐2 and NF‐&kgr;B pathways

  2019cites this paper
• Efficacy of Diphenhydramine Hydrochloride Tablet Prophylaxis for Oxaliplatin Hypersensitivity Reaction and Pharmacoeconomic Study

  2019cites this paper
• Mechanistic insight on the chemistry of potential Pt antitumor agents as revealed by collaborative research performed in Kragujevac and Erlangen

  2019cites this paper
• Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy

  2019cites this paper
• Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test.

  2018cites this paper
• Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.

  2018cites this paper
• Platinum coordination compounds with potent anticancer activity

  2017cites this paper
• Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.

  2017cites this paper
• Systems Chronotherapeutics

  2017cites this paper
• Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology - From Drug Discovery to Nanocarrier Design and Development.

  2017cites this paper
• Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study

  2017cites this paper
• On the use of liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemotherapeutic agents

  2016influential citation
• Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.

  2015cites this paper
• A comparative study: effect of platinum compounds viz. cisplatin, carboplatin and oxaliplatin on blood parameters

  2015cites this paper
• Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

  2015cites this paper
• Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.

  2015cites this paper
• Pharmacokinetics and hematotoxicity of a novel copper‐based anticancer agent: Casiopeina III‐Ea, after a single intravenous dose in rats

  2014cites this paper
• Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells

  2014cites this paper
• Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.

  2014cites this paper
• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• 切除不能胃癌 7 例に対する化学療法中の有害事象と血清アルブミン濃度の関連性

  2013cites this paper
• Liposomes, a promising strategy for clinical application of platinum derivatives

  2013cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival

  2013cites this paper
• Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC)

  2013cites this paper
• Role of Pharmacogenetics in Gastrointestinal Cancer

  2012cites this paper
• Inductively Coupled Plasma Mass Spectrometry for Analysis of Metal‐Containing Pharmaceuticals

  2012cites this paper
• Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines

  2012cites this paper
• Novel drugs targeting microtubules: the role of epothilones.

  2012cites this paper
• Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance

  2012cites this paper
• THE EFFECT OF CIRCADIAN RHYTHM ON VECURONIUM INDUCED NEUROMUSCULAR BLOCK VEKÜRONYUMA BA⁄LI NÖROMUSKÜLER BLOKAJ ÜZER‹NE S‹RKAD‹YEN R‹TM‹N ETK‹S‹ KLİNİK ÇALIŞMA / CILINICAL RESEARCH

  2012cites this paper
• THE EFFECT OF CIRCADIAN RHYTHM ON VECURONIUM INDUCED NEUROMUSCULAR

  2012cites this paper
• Pharmacokinetics of Oxaliplatin in Gastrointestinal Cancer Patients with Malignant Ascites

  2011cites this paper
• Hepatic necrosis and hemorrhage following hyperthermic intraperitoneal chemotherapy with oxaliplatin: A review of two cases.

  2011cites this paper
• Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy

  2011cites this paper
• Determination of the binding sites for oxaliplatin on insulin using mass spectrometry-based approaches

  2011cites this paper
• Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy

  2011cites this paper
• Recherche de biomarqueurs de la neurotoxicité des traitements anticancéreux à base d'oxaliplatine: approche protéomique quantitative

  2011cites this paper
• Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptors.

  2011cites this paper
• TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo

  2011cites this paper
• Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation

  2011cites this paper
• LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds.

  2010cites this paper
• Is Platinum Present in Blood and Urine from Treatment Givers during Hyperthermic Intraperitoneal Chemotherapy?

  2010cites this paper
• A Case of Autoimmune Hemolytic Anemia Caused by Repeated Administration of Oxaliplatin

  2010cites this paper
• New oral anticoagulants: a practical guide for clinicians

  2010cites this paper
• Circadian timing in cancer treatments.

  2010cites this paper